Biological
Nadunolimab
Nadunolimab is a biological therapy with 4 clinical trials. Currently 3 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
3(75%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
3
75%
Ph phase_2
1
25%
Phase Distribution
3
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
3(75.0%)
Phase 2Efficacy & side effects
1(25.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
3
trials recruiting
Total Trials
4
all time
Status Distribution
Active(3)
Completed(1)
Detailed Status
Recruiting3
Completed1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
3
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 13 (75.0%)
Phase 21 (25.0%)
Trials by Status
recruiting375%
completed125%
Recent Activity
3 active trials
Showing 4 of 4
recruitingphase_2
Immunoprevention for High-risk Lung Lesions
NCT07284485
completedphase_1
Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer.
NCT05181462
recruitingphase_1
A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
NCT06548230
recruitingphase_1
Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC
NCT07281716
Clinical Trials (4)
Showing 4 of 4 trials
NCT07284485Phase 2
Immunoprevention for High-risk Lung Lesions
NCT05181462Phase 1
Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer.
NCT06548230Phase 1
A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
NCT07281716Phase 1
Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC
All 4 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 4